Clinical Trial

Experimental Treatment for Patients with Lymphoma

Study Description

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - KPT-9274

Drug - KPT-9274 & Niacin ER

Additional Information

Official Study Title

A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

Clinical Trial ID

NCT02702492

ParticipAid ID

DbDEkd